PRESS RELEASE published on 12/27/2022 at 07:45 from NANOBIOTIX NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
